Navigation Links
Lexicon Completes Phase 2 Study Of LX1033 In IBS-d
Date:12/3/2013

THE WOODLANDS, Texas, Dec. 3, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d). LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.

The primary endpoint of this study was the change in stool consistency averaged from baseline to day 28. All treatment groups, including placebo, showed significant improvements over time, yet differences between placebo and LX1033 in stool consistency were not statistically significant. Further analyses of the stool consistency data were performed adjusting for early terminations which may have enhanced the placebo response rate. These additional analyses of stool consistency yielded favorable results for the LX1033 500mg three times daily dose group compared to placebo, and some of these findings were associated with statistically significant results (p<0.05). LX1033 reduced the production of plasma 5-HIAA (a biomarker for serotonin synthesis) significantly more than placebo, with the greatest reductions observed in the 500 mg three times daily dose group. This same LX1033 dose also produced the greatest reduction in abdominal pain, an important measure of efficacy in IBS-d. The proportion of patients showing an abdominal pain intensity weekly response (defined as a reduction in abdominal pain of at least 30% from baseline for at least 50% of the weeks assessed, with no worsening from baseline in stool consistency) was 33% on placebo and 47% on LX1033 500 mg given three times daily (p<0.05). LX1033 was safe and well tolerated in the study, with adverse events evenly distributed among LX1033 treatment arms and placebo.

"While LX1033 showed similar improvements in stool consistency as compared to the placebo patients who completed the study, there were positive effects on abdominal pain in the treated group that warrant further study," said Pablo Lapuerta, M.D., Lexicon's chief medical officer. "While this initial Phase 2a study was underway, we completed long-term toxicology studies which would allow us to conduct a Phase 2b study at doses informed by the current results and with a duration of 12 weeks, a treatment period that has historically been important to identify clinically meaningful changes as compared to placebo."

In this Phase 2 study of IBS-d, 373 patients were randomized to be treated for 28 days with either placebo or one of three different dose levels of LX1033 for 28 days, 1000 mg twice daily, 500 mg twice daily, and 500 mg three times daily. The primary endpoint was the change from baseline in stool consistency as evaluated by the Bristol Stool Form Scale. A key secondary endpoint was the change from baseline in abdominal pain, and other endpoints included the change in plasma 5-HIAA.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1033, characterizations of the results of and projected timing of clinical trials of LX1033, and the potential therapeutic and commercial potential of LX1033.  The press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1033 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Tie-up with ... initiative to save newborns   Fortis ... & newborns in collaboration with Breast Milk Foundation (BMF), a ... Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit ... source for infants and should be available to babies deprived ...
(Date:4/27/2016)... YORK , April 27, 2016 ... OASM ), a developer of a new generation ... announced positive overall survival results for Paclical/Apealea in ... of 789 patients with epithelial ovarian cancer. These ... groups: Paclical/Apealea in combination with carboplatin versus Taxol ...
(Date:4/26/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO) is pleased ... Pharm D., to Vice President of Education and Quality. ... will continue to lead and oversee Diplomat University, an ... and training to Diplomat employees and external professionals on ... also houses the quality assurance department, which focuses on ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... In an article ... shares her enthusiasm for Botox and lip injections, which she underwent in order to ... Coachella Valley Music and Arts Festival. The article explains that Ms. Mirmelli’s situation is ...
(Date:4/29/2016)... ... , ... Our bodies are bombarded daily by environmental and lifestyle factors that ... is to adopt a more healthful diet, but too many people think that food ... Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, disagrees ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House announced ... loans, more information about their loan terms and accounts, and more protections for ... including federal and private loans, has reached $1.3 trillion, with 43 million Americans ...
(Date:4/29/2016)... ... ... Spine Team Texas, a comprehensive spine physician group specializing in the treatment ... been invited to be a featured speaker at the Texas Society of the American ... 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, will ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... Canadian Celiac Association (CCA), is pleased to announce the launch of the ... nutritional articles, recipes, and more. The purpose of the GFCP Scoop ...
Breaking Medicine News(10 mins):